

RealRate

PHARMACEUTICAL 2021

Syndax Pharmaceuticals Inc Rank 91 of 402





Syndax 🌮



PHARMACEUTICAL 2021



Syndax Pharmaceuticals Inc Rank 91 of 402



The relative strengths and weaknesses of Syndax Pharmaceuticals Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Syndax Pharmaceuticals Inc compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 101% points. The greatest weakness of Syndax Pharmaceuticals Inc is the variable Liabilities, Non-Current, reducing the Economic Capital Ratio by 21% points.

The company's Economic Capital Ratio, given in the ranking table, is 207%, being 159% points above the market average of 47%.

Input Variable	Value in 1000 USD
Assets, Current	298,864
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	18,872
Liabilities, Non-Current	29,553
Other Assets	1,557
Other Compr. Net Income	-4.0
Other Expenses	0
Other Liabilities	0
Other Net Income	-1,735
Other Revenues	1,517
Property and Equipment	192
Research and Development	50,435
Selling, General and Administrative Expense	22,505

Output Variable	Value in 1000 USD
Assets	300,613
Liabilities	48,425
Expenses	72,940
Revenues	1,517
Stockholders Equity	252,188
Net Income	-73,158
Comprehensive Net Income	-73,160
Economic Capital Ratio	207%

